EPASARIKAN

Aceh
Nias

Bahasa Indonesia
	Tentang Proyek

	Harga

	Statistik

	Direktori

	Peluang Pasar

	Profil NAD

	Buletin

	Warta FMIS

	Warta Internasional

	Links

	Kontak

	Pertanyaan

	Photo Gallery

Novartis Chile SA, a Chilean affiliate of the Swiss-based pharmaceutical company Novartis AG, has secured registration in Chile for its vaccine to prevent the infectious salmon anaemia (ISA) virus. Novartis has for years-been developing and producing vaccines, including viral antigens against ISA. It produced the first ISA vaccine in Canada in 1999 and currently has a portfolio of ISA vaccines that are marketed in Canada, the Faroe Islands, Norway and Chile, amounting to more than 200 million fish vaccinated over 10 years.

According to Constantino Siderakis, the marketing and sales manager of the company's aquaculture business, the new vaccine is a product designed for Chile and corresponds to a second generation of ISA vaccines, which was obtained with a new formulation to increase the efficiency and specific immunity against the virus. The vaccine is produced in Canada at one of the company's plants on Prince Edward Island.

Copyright 2009 INFOFISH | All Rights Reserved. Disclaimer

This site is best viewed using current versions of Microsoft Internet Explorer,Google Chrome,Firefox at a screen resolution of 1024 x 768 or higher.